P. Lewis et al., WHOLE-BODY F-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IN PREOPERATIVE EVALUATION OF LUNG-CANCER, Lancet, 344(8932), 1994, pp. 1265-1266
Despite use of computed tomography, some lung cancer patients are foun
d to have unresectable disease at surgery, or they present early with
metastases. We studied whether whole-body -positron emission tomograph
y (PET) with F-18-fluorodeoxyglucose ((18)FDG) would improve the preop
erative detection of metastases. We retrospectively analysed 34 patien
ts with ''operable'' non-small-cell lung cancer who underwent (18)FDG
PET after routine assessment. Management changes produced by the PET s
can and confirmatory tests were reviewed. PET unsuspected malignant le
sions in 10 (29%) Management changes occurred in 14 (41%), including 6
(18%) patients who were changed to non-surgical therapy. These data s
uggest that whole-body (18)FDG PET improves preoperative assessment of
lung cancer patients.